Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression
Johnson & Johnson’s Strategic Acquisition of Intra-Cellular Therapies: Balancing Short-term Dilution with Long-term Growth Potential
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim
Johnson & Johnson Makes Biopharmaceutical Splash with $14.6B Intra-Cellular Deal
Johnson & Johnson just announced a major acquisition to boost its position in the biopharmaceutical market. Quantum computing stocks fell 40% after Nvidia's CEO shared his outlook for the industry. See the details.
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
Key Takeaways Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company.Intra-Cellular shareholders will get $132 per share,
Hold Rating Reiterated for Intra-Cellular Therapies Amid Johnson & Johnson Acquisition at $132 per Share
In a report released today, Jeffrey Hung from Morgan Stanley downgraded Intra-Cellular Therapies (ITCI – Research Report) to a Hold, with a
J&J strikes $14.6 billion deal for Intra-Cellular Therapies
Johnson & Johnson on Monday said that it's agreed to acquire CNS biotech Intra-Cellular Therapies for $14.6 billion in cash, or $132 per share. Why it matters: This would be the largest biotech merger since 2023,
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash,
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
J&J Stock Falls After Company Pauses Use of Heart Device
Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...
D Magazine1d
The Dallas Company That Could End an $8 Billion Johnson & Johnson Talc Powder Lawsuit
This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary filed a voluntary prepackaged Chapter 11 bankruptcy case to resolve ...
S&P Places Johnson & Johnson on CreditWatch Negative
S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.
The Motley Fool5d
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Morningstar7d
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's ...
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...